Table 2.
Characteristics of the 45 patients collected in our national multicenter cohort.
| Characteristics | All patients (N = 45) | Characteristics | All patients (N = 45) |
|---|---|---|---|
| Demographics | ICI-BP diagnosis | ||
| Sex, No. (%) male/female | 41 (91)/4 (9) | Histopathologic examination | No. (%) |
| Age (years), median (range) | 74 (46–90) | Yes | 28 (62) |
| Tumor type | No. (%) | No | 17 (38) |
| NSCLC | 18 (40) | DIF | No. (%) |
| Melanoma | 12 (27) | Yes | 31 (69) |
| Colorectal adenocarcinoma | 5 (11) | No | 14 (31) |
| Renal clear cell carcinoma | 5 (11) | IIF | No. (%) |
| HNSCC | 4 (9) | Yes | 26 (58) |
| Urothelial carcinoma | 1 (2) | No | 19 (42) |
| Tumor stage | No. (%) | BP180 autoantibodies | No. (%) |
| Stage IV | 33 (73) | Positive | 30 (66) |
| Stage III | 9 (20) | Negative | 12 (27) |
| Other or NR | 3 (7) | Not performed | 3 (7) |
| Immunotherapy | No. (%) | BP230 autoantibodies | No. (%) |
| Nivolumab | 28 (62) | Positive | 15 (33) |
| Pembrolizumab | 11 (24) | Negative | 26 (58) |
| Nivolumab + ipilimumab | 2 (5) | Not performed | 4 (9) |
| Cemiplimab | 2 (5) | ICI management | No. (%) |
| Spartalizumab | 1 (2) | ICI temporarily held | 16 (36) |
| Atezolizumab | 1 (2) | BP flare after rechallenged with the same ICI | 7 (16) |
| ICI-BP features | Median (range) | ICI permanently discontinued | 17 (38) |
| Time to symptoms onset after ICI initiation (weeks) | 35 (4–260) | ICI-BP management | |
| Time to BP diagnosis after ICI initiation (weeks) | 48 (5–286) | First line therapy | No. (%) |
| First manifestations | No. (%) | Topical costicosteroid | 4 (9) |
| Pruritus without other manifestations | 19 (42) | Topical corticosteroid + systemic corticosteroid | 41 (91) |
| Eczematous eruption | 11 (24) | Second line therapy | No. (%) |
| Bullous lesions | 9 (20) | Doxycycline | 5 (11) |
| Urticarial eruption | 7 (16) | Dapsone | 3 (7) |
| Mucositis | 3 (7) | Third line therapy | No. (%) |
| Papular lesions | 1 (2) | Dupilumab | 1 (2) |
| Mucosal membrane involvement | No. (%) | ICI-BP response | No. (%) |
| No | 37 (82) | Partial to complete resolution | 38 (84) |
| Yes | 8 (18) | Refractory symptoms | 7 (16) |
| CTCAE grade | No. (%) | Tumor response | No. (%) |
| 1 | 12 (27) | CR or PR | 9 (20) |
| 2 | 15 (33) | SD | 16 (36) |
| 3 | 17 (38) | PD | 11 (24) |
| 4 | 1 (2) | NR | 9 (20) |
All patients developed ICI-induced BP. The information reported is about patients’ demographics, primary cancer, immunotherapy, and ICI-induced BP. ICI, immune checkpoint inhibitor; BP, bullous pemphigoid; NSCLC, non-small-cell lung cancer; HNSCC, head and neck squamous cell carcinoma; NR, not reported; CTCAE, Common Terminology Criteria for Adverse Events; DIF, direct immunofluorescence; IIF, indirect immunofluorescence; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.